Phase 3
Completed N=199
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
tuberous sclerosis complex · Seizures
Source: ClinicalTrials.gov NCT02544750 ↗
Enrolled (actual)
199
Serious AEs
28.1%
Results posted
Jul 2022
Primary outcomePrimary: Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) — 117; 75; 80; 60 Participants
◆ Published Evidence
Highly cited
104citations · ~26 / year
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.
Summary
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.
Linked Publications
-
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) |
117; 75; 80; 60; 11; 7 | — |
| PRIMARY Number of Participants With Any TEAE, by Severity |
35; 16; 63; 48; 19; 11 | — |
| SECONDARY Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period |
-55.66; -46.76 | — |
| SECONDARY Number of Participants Considered Treatment Responders During the OLE Treatment Period |
70; 36; 54; 39 | — |
| SECONDARY Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period |
3.2; 3.4; 4.0; 2.7; 3.2; 3.3 | — |
| SECONDARY Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period |
-55.18; -46.76 | — |
Eligibility Criteria
Key Inclusion Criteria
- Completion of the GWEP1521 Blinded Phase
Data sourced from ClinicalTrials.gov (NCT02544750) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.